Oncology
Lamivudine prevents hepatitis B virus reactivation in cancer patients
Published in Hepatitis Weekly, April 12th, 2004
"Although hepatitis B virus (HBV) reactivation in HBV carriers undergoing immunosuppressive therapy is clearly documented, the role of antiviral prophylaxis in such individuals is still controversial. The aim of this study was to determine the efficacy of lamivudine prophylaxis in HBV carriers with hemato/oncological malignancies who receive chemotherapy. Eighteen HBV carriers with malignancy, who were candidates for chemotherapy, were enrolled," scientists in Turkey report.
"Eight subjects (three with leukemia, four with lymphoma and one with multiple myeloma) were enrolled for...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2004-04-12)
More Articles from Hepatitis Weekly
- Chronic Hepatitis C
Urinary nitrite/nitrate reveals the success of common hepatitis C therapy - Addiction Medicine
Liver transplantations are acceptable for disulfiram-linked liver failure - Chronic Viral Hepatitis
Age, sex, and fibrosis impact findings in chronic hepatitis C patients - Drug Development
Hepatitis C virus p7 protein is a potential target for antiviral therapy - Hepatology
Liver interferon 1 receptors predict response in chronic hepatitis C patients - Adverse Drug Effects
Interferons used for treating multiple sclerosis raise liver enzyme levels - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
